Abstract

NEWER ANTIVIRAL DRUGS FOR THE MANAGEMENT OF HEPATITIS C INFECTION IN POST RENAL TRANSPLANT PATIENT

Dr. Sincy Mery Chacko*, Dr. Divya Gopinath, Dr. Abel Abraham Thomas, Dr. Miliya Merry Gladson, Dr. Hima S. Shekar

Abstract

Introduction: Chronic infection with hepatitis C virus (HCV) has been found to an important health problem worldwide. The management of HCV was difficult in kidney transplant patient before the introduction of DAA. The present study was carried out to find the efficacy of the newer antiviral drugs in the management of hepatitis c infection in post renal transplant patient. Methods: Retrospective study and prospective study was carried out in 199 patients from 2009 to 2015. Relevant information was obtained from the Old Patient case records and follow up. Results: Of the 9 cases 7 were male and 2 were females, mean age was 38.2 +/- 11.4 yrs. Among them 6 were positive for HCV pre transplantation. 8 patients were genotype 1 and remaining one was genotype 111. The mean pretreatment HCV viral load was 7375753.78 +/- 4364095IU/ml. All patients continued their immunosuppression therapy according to course of therapy and graft function. Intended duration of therapy for all patients was 24weeks. During therapy 4week viral load was available and was undetectable in 7 patients. And at 12weeks all were undetectable. Out of 9 patients who were given with ribavirin 5 was found to be anemic. Conclusions: The newer antivirals such as DAA shows higher safety and good efficacy in patients who were contraindicated for interferon.

Keywords: Hepatitis C, Anti Viral, Ribavirin, Interferon, Viral Load, Direct-Acting Antivirals, Sobosfovir.